Pacific Biosciences
PACB
274 hedge funds and large institutions have $2.76B invested in Pacific Biosciences in 2023 Q4 according to their latest regulatory filings, with 50 funds opening new positions, 103 increasing their positions, 75 reducing their positions, and 45 closing their positions.
146% more call options, than puts
Call options by funds: $54M | Put options by funds: $22M
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
37% more repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 75
26% more capital invested
Capital invested by funds: $2.2B → $2.76B (+$566M)
11% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 45
0.87% more ownership
Funds ownership: 104.41% → 105.29% (+0.87%)
0% more funds holding
Funds holding: 273 → 274 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$72.2M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$38.3M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$28.7M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$23.8M |
| 5 |
JSP
Jackson Square Partners
Larkspur,
California
|
+$22.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$33M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$21.3M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$10M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$9.78M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
-$9.42M |
PACB Hedge Fund Activity: Q4 2023 in Review
274 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q4 2023, worth a combined $2.76B — up 26% from $2.2B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new PACB positions and 45 closed out — a net gain of 5 holders — while 103 added to existing stakes and 75 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $72.2M. The largest seller was Farallon Capital Management, cutting an estimated $33M.
- 274 institutional investors held Pacific Biosciences (PACB) as of Q4 2023, up from 273 in Q3 2023.
- Funds reported $2.76B of Pacific Biosciences stock for Q4 2023, up 26% quarter-over-quarter.
- 50 funds opened new Pacific Biosciences positions in Q4 2023 and 45 closed out, a net change of +5 holders.
- The largest Pacific Biosciences buyer in Q4 2023 was Morgan Stanley, an estimated $72.2M added.
- The largest Pacific Biosciences seller in Q4 2023 was Farallon Capital Management, an estimated $33M sold.
Based on aggregated 13F filings for Q4 2023.